The role of p53 in the immunobiology of cutaneous squamous cell carcinoma

Clinical and Experimental Immunology

Volumn 132, Issue 3, 2003, Pages 379-384

  Black, A P B ^a   Ogg, Graham S ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic T lymphocytes; Human papillomavirus; p53; Squamous cell carcinoma

Indexed keywords

PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOCOMPETENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOCOMPETENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS;

EID: 0038810242     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02159.x     Document Type: Review

References (85)

1. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344:975-83.
2. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49:506-9.
3. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10124-8.
4. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372:773-6.
5. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 1997; 133:1263-70.
6. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000; 42: 11-7.
7. Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54:2914-8.
8. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000; 910:121-37.
9. Coulter LK, Wolber R, Tron VA. Site-specific comparison of p53 immunostaining in squamous cell carcinomas. Hum Pathol 1995; 26:531-3.
10. Liang SB, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Chen BK, Sonobe H. Sun-exposure- and aging-dependent p53 protein accumulation results in growth advantage for tumour cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 1999; 434:193-9.
11. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649-54.
12. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB. Generation of T cells specific for the wild-type sequence p53(264-272): peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000; 165:5938-44.
13. Hoffmann TK, Donnenberg AD, Finkelstein SD et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272): peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62:3521-9.
14. Theobald M, Ruppert T, Kuckelkorn U et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998; 188:1017-28.
15. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185:833-41.
16. Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000; 164:596-602.
17. Hernandez J, Ko A, Sherman LA. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 2001; 166:3908-14.
18. Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 1995; 25:1638-42.
19. Bertholet S, Iggo R, Corradin G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 1997; 27:798-801.
20. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001; 53:357-64.
21. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272): epitope. J Immunol 2002; 168:1338-47.
22. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93:4781-6.
23. Moch C, Moysan A, Lubin R et al. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies. Br J Cancer 2001; 85:1883-6.
24. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, Offringa R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000; 60:5508-13.
25. Houbiers JG, Nijman HW, van der Burg SH et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23:2072-7.
26. Nijman HW, Houbiers JG, van der Burg SH, Vierboom MP, Kenemans P, Kast WM, Melief CJ. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 1993; 14:121-6.
27. Zeh HJ III, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ. Flow-cytometric determination of peptide-class 1 complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 1994; 39:79-86.
28. Stuber G, Leder GH, Storkus WT et al. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994; 24:765-8.
29. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160:328-33.
30. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000; 49:417-25.
31. Ferries E, Connan F, Pages F et al. Identification of p53 peptides recognized by CD8 (+) T lymphocytes from patients with bladder cancer. Hum Immunol 2001; 62:791-8.
32. Ropke M, Hald J, Guldberg P et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996; 93:14704-7.
33. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999; 5:1281-8.
34. Eura M, Chikamatsu K, Katsura F et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6:979-86.
35. Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA- A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 2000; 51:128-33.
36. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7:127-35.
37. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH. Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. Int J Cancer 2001; 93:855-61.
38. Wurtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002; 99:568-72.
39. Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998; 28:305-16.
40. Fedoseyeva EV, Boisgerault F, Anosova NG, Wollish WS, Arlotta P, Jensen PE, Ono SJ, Benichou G. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 2000; 164:5641-51.
41. Tilkin AF, Lubin R, Soussi T er al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995; 25:1765-9.
42. van der Burg SH, de Cock K, Menon AG et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001; 31:146-55.
43. Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RS. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995; 19: 352-8.
44. Patel A, Halliday GM, Barnetson RS. CD4+ T lymphocyte infiltration correlates with regression of a UV- induced squamous cell carcinoma. J Dermatol Sci 1995; 9:12-9.
45. Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997; 186:695-704.
46. Hilburger Ryan M, Abrams SI. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 2001; 49:603-12.
47. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92:11993-7.
48. McCarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JD. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58:2601-5.
49. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines. J Exp Med 1996; 183:1357-65.
50. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP. Dendritic cells transduced with wild-type p53 gene elicit potent anti- tumour immune responses. Clin Exp Immunol 1999; 117:244-51.
51. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002; 9:345-52.
52. Petersen TR, Bregenholta S, Pedersen LO, Nissen MH, Claesson MH. Human p53(264-272): HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett 1999; 137:183-91.
53. Chen B, Timiryasova TM, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther 2000; 7:1437-47.
54. Rosenwirth B, Kuhn EM, Heeney JL, Hurpin C, Tartaglia J, Bonnet MC, Moingeon P, Erdile L. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine 2001; 19:1661-70.
55. van der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002; 8:1019-27.
56. Kuball J, Schuler M, Antunes Ferreira E et al. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 2002; 9:833-43
57. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papillomaviruses.. Int J Exp Pathol 2001; 82:15-33.
58. Kessis TD, Slebos RJ, Nelson WG. et al. Human papillomavirus 16, E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993; 90:3988-92.
59. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 1992; 89:4549-53.
60. Berezutskaya EYuB, Morozov A, Raychaudhuri P, Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 1997; 8:1277-86.
61. Luxton J, Shepherd P. Human papillomavirus antigens and T-cell recognition. Curr Opin Infect Dis 2001; 14:139-43.
62. Orth G, Favre M, Majewski S, Jablonska S. Epidermodysplasia verruciformis defines a subset of cutaneous human papillomaviruses. J Virol 2001; 75:4952-3.
63. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus- induced genetic cancer of the skin. Arch Dermatol 1995; 131:1312-8.
64. Cohen EB, Komorowski RA, Clowry LJ. Cutaneous complications in renal transplant recipients. Am J Clin Pathol 1987; 88:32-7.
65. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H, de Villiers EM. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994; 54:4610-3.
66. de Jong-Tieben LM, Berkhout RJ, Smits HL, Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, ter Schegget J. High frequency of detection of epidermodysplasia verruciformis- associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995; 105:367-71.
67. Shamanin V, zur Hausen H, Lavergne D et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88:802-11.
68. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre) malignant skin lesions from renal transplant recipients. J Clin Microbiol 2000; 38:2087-96.
69. Meyer T, Arndt R, Christophers E, Stockfleth E. Frequency and spectrum of HPV types detected in cutaneous squamous-cell carcinomas depend on the HPV detection system: a comparison of four PCR assays. Dermatology 2000; 201:204-11.
70. Harwood CA, Spink PJ, Surentheran T, Leigh IM, de Villiers EM, McGregor JM, Proby CM, Breuer J. Degenerate and nested PCR. a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol 1999;37:3545-55.
71. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM. Human papillomavirus infection and nonmelanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61:289-97.
72. Harwood CA, Proby CM. Human papillomaviruses and nonmelanoma skin cancer. Curr Opin Infect Dis 2002; 15:101-14.
73. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000; 74:11636-41.
74. Bouwes Bavinck JN, Stark S, Petridis AK et al. The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses. Br J Dermatol 2000; 142:103-9.
75. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229-34.
76. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-100.
77. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A, Matlashewski G. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000; 87:528-33.
78. McGregor JM, Harwood CA, Brooks L et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002; 119:84-90.
79. Marshall SE, Bordea C, Wojnarowska F, Morris PJ, Welsh KI. p53 codon 72 polymorphism and susceptibility to skin cancer after renal transplantation. Transplantation 2000; 69:994-6.
80. Bastiaens MT, Struyk L, Tjong AHSP et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog 2001; 30:56-61.
81. O'Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJ. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 2001; 54:539-42.
82. Gustafsson AC, Guo Z, Hu X et al. HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm Venereol 2001; 81: 125-9.
83. Purdie KJ, Pennington J, Proby CM, Khalaf S, de Villiers EM, Leigh IM, Storey A. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J 1999; 18:5359-69.
84. Ruhland A, de Villiers EM. Opposite regulation of the HPV 20-URR and HPV 27-URR promoters by ultraviolet irradiation and cytokines. Int J Cancer 2001; 91:828-34.
85. YuZ, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002; 110:289-94.